Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 07, 2018
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Paliperidone Extended-Release Tablets Obtains Drug Registration Approval
Details : Paliperidone Extended Release tablets is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 14, 2023
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Johnson & Johnson | Taipei Institute of Pathology
Deal Size : Inapplicable
Deal Type : Inapplicable
Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2014
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Johnson & Johnson | Taipei Institute of Pathology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2012
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 21, 2012
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 10, 2012
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 10, 2012
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2012
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2012
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2012
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable